ATON
AlphaTONยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATON
Alphaton Capital Corp
A clinical stage immunooncology company
Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110
--
AlphaTON Capital Corp was incorporated in Ontario in 1973. AlphaTON is a clinical-stage immuno-oncology company that believes it will be a first-in-class therapy for cancer avoidance in patients with known checkpoint resistance pathways to improve long-term treatment response and quality of life. AlphaTON is currently working on nine immuno-oncology assets, five of which are in the preclinical stage and four in the clinical stage. AlphaTON drug development pipeline products include biological-based product candidates or technologies to address known resistance pathways/mechanisms of current checkpoint inhibitors based on identified scientific principles, including intratumoral delivery, nanoparticles, liposomes, aptamers and virus-like particles.
Company Financials
EPS
ATON has released its 2025 Q2 earnings. EPS was reported at -1.26, versus the expected 0, missing expectations. The chart below visualizes how ATON has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
